Measles: the UK’s next epidemic?
March 6, 2024MMR, measles, vaccines
Recently, the UK has seen a rapid increase in the number of cases of measles, along with a drop in …
FDA approves Sandoz’s denosumab biosimilars
March 6, 2024Medical Communications FDA, Jubbonti, Musculo-skeletal disorder, Sandoz, Wyost, denosumab
Sandoz has announced that the US Food and Drug Administration (FDA) has approved Wyost (denosumab-bbdz) and Jubbonti (denosumab-bbdz), which are …
Regenxbio announces initial efficacy data from phase 1/2 AFFINITY DUCHENNE trial
March 6, 2024Research and Development Duchenne Muscular Dystrophy, Musculo-skeletal disorder, Regenxbio, clinical trial
Regenxbio has announced additional interim safety data from its phase 1/2 AFFINITY DUCHENNE trial of RGX-202 in patients with Duchenne …
GSK’s Jemperli recommended by NICE for endometrial cancer treatment
March 5, 2024Medical Communications GSK, Jemperli, NICE, Oncology, endometrial cancer
GSK has announced that the National Institute for Health and Care Excellence (NICE) has recommended the use of Jemperli (dostarlimab) …
Novartis shares new data for Zolgensma in children with SMA
March 5, 2024Musculo-skeletal disorder, Novartis, Zolgensma, sma, spinal muscular atrophy
Novartis has announced new data to continue the support of the clinical benefits of Zolgensma (onasmenogene abeparvovec), for the treatment …
FDA approves J&J’s Rybrevant with chemotherapy for NSCLC treatment
March 4, 2024Medical Communications FDA, Johnson & Johnson, NSCLC, Oncology, Rybrevant
Johnson & Johnson have announced that the US Food and Drug Administration (FDA) has approved Rybrevant (amibantamab-vmjw) following a priority …
EMA validates two applications for datopotamab deruxtecan for cancer treatments
March 4, 2024Medical Communications CHMP, Daiichi Sankyo, EMA, Oncology, datopotamab deruxtecan
AstraZeneca has announced that the European Medicines Agency (EMA) has validated to marketing authorisation applications (MAAs) for AstraZeneca and Daiichi …
Cardiff Oncology doses first patient in colorectal cancer trial
March 1, 2024Research and Development Cardiff Oncology, Oncology, clinical trial, colorectal cancer
Cardiff Oncology has announced that it has dosed the first patient in its randomised first-line phase 2 trial, CRDF-004, for …
Viracta Therapeutics completes enrolment for T-cell lymphoma cohort in NAVAL-1 trial
March 1, 2024Medical Communications Oncology, Viracta Therapeutics, lymphoma
Viracta Therapeutics has announced that it has completed stage 2 enrolment into the relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) …
AstraZeneca’s Voydeya recommended for approval in EU by CHMP
February 29, 2024Medical Communications AstraZeneca, CHMP, EMA, Haematology, Voydeya
AstraZeneca has announced that Voydeya (danicopan) has been recommended for marketing authorisation in the European Union (EU) by the Committee …
Spero Therapeutics’ bacterial infection treatment gains FDA IND clearance
February 29, 2024Medical Communications FDA, Infections and infestations, Spero Therapeutics, bacterial infections, investigational new drug
Spero Therapeutics has announced that it has gained US Food and Drug Administration (FDA) clearance for the investigational new drug …
Viatris and Idorsia enter research and development collaboration
February 28, 2024Research and Development Idorsia, Pharmacy, Viatris, acute myocardial infarction, systemic lupus erythematosus
Viatris and Idorsia have announced that they have entered into agreements for a significant global research and development collaboration. Under …
Amneal and Zambon Biotech enter agreement for Parkinson’s treatment
February 28, 2024Research and Development Amneal pharmaceuticals, Neurology, Parkinson's disease, Zambon Biotech, licensing agreement
Amneal Pharmaceuticals has announced that it has entered into an exclusive licensing agreement with Zambon Biotech for IPX204 in the …
GSK shares positive results from phase 3 trial for gonorrhoea treatment
February 27, 2024Research and Development GSK, Infections and infestations, antibiotic, clinical trial, gonorrhoea
GSK has announced positive headline results from its phase 3 EAGLE-1 trial for gepotidacin, its potential first-in-class oral antibiotic with …
Amgen opens new biomanufacturing facility in Ohio, US
February 27, 2024Manufacturing and Production Amgen, Biomanufacturing, Manufacturing Facility, Ohio, Pharmacy, US
Amgen has announced that it has opened a new manufacturing site in Central Ohio, US. This will be the latest …
Roche shares data from phase 3 trial of Xolair as allergy treatment
February 26, 2024Research and Development Allergic Disorders, Roche, Xolair, allergy, clinical trial, food allergy
Roche has announced data from stage 1 of the National Institutes of Health (NIH)-sponsored phase 3 OUtMATCH trial, which assessed …
Boehringer Ingelheim announces results from phase 2 trial for liver disease treatment
February 26, 2024Research and Development Boehringer Ingelheim, Hepatology, clinical trial, liver disease, survodutide
Boehringer Ingelheim has announced results from the phase 2 trial of survodutide for the treatment of liver disease due to …
AbbVie and Tentarix collaborate on oncology and immunology treatments
February 23, 2024Research and Development AbbVie, Oncology, collaboration, immunology
AbbVie and Tentarix Biotherapeutics have announced that they have entered a multi-year collaboration focused on the discovery and development of …
Almirall licenses Novo Nordisk’s anti-IL-21 monoclonal antibody for dermatology treatment
February 23, 2024Research and Development Almirall, Dermatology, Novo Nordisk, dermatology, monoclonal antibody
Almirall has announced that it has entered into an exclusive license agreement with Novo Nordisk for the rights to its …
FDA accepts BLA for Regeneron’s linvoseltamab for Priority Review
February 22, 2024Medical Communications FDA, Oncology, Regeneron, bla, priority review
Regeneron Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
